B. Metzler seel. Sohn & Co. AG Acquires 9,673 Shares of Solventum Co. (NYSE:SOLV)

B. Metzler seel. Sohn & Co. AG increased its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 292.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,986 shares of the company's stock after acquiring an additional 9,673 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Solventum were worth $858,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP boosted its position in shares of Solventum by 22.7% during the 4th quarter. Wellington Management Group LLP now owns 8,504 shares of the company's stock valued at $562,000 after acquiring an additional 1,571 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its position in Solventum by 16.4% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 5,175 shares of the company's stock valued at $342,000 after purchasing an additional 731 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Solventum by 41.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company's stock worth $78,833,000 after buying an additional 347,669 shares in the last quarter. Allstate Corp bought a new position in shares of Solventum in the 4th quarter worth $288,000. Finally, DnB Asset Management AS raised its position in shares of Solventum by 12.3% during the 4th quarter. DnB Asset Management AS now owns 26,043 shares of the company's stock valued at $1,720,000 after buying an additional 2,844 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SOLV. Piper Sandler upped their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. Wells Fargo & Company increased their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. Morgan Stanley raised their price objective on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group upped their target price on Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Finally, Bank of America lifted their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, Solventum currently has an average rating of "Hold" and a consensus target price of $79.86.

Solventum Trading Up 2.6 %

Shares of NYSE SOLV traded up $1.69 during mid-day trading on Tuesday, hitting $67.01. The stock had a trading volume of 279,094 shares, compared to its average volume of 1,361,170. The business has a 50 day moving average price of $75.23 and a two-hundred day moving average price of $71.90. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The firm has a market cap of $11.59 billion and a P/E ratio of 24.37.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.